Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2005-03-30
2009-08-04
Coleman, Brenda L (Department: 1624)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C544S262000
Reexamination Certificate
active
07569572
ABSTRACT:
This invention relates to compounds of formula (I).
REFERENCES:
patent: 3951980 (1976-04-01), Henry et al.
patent: 4282631 (1981-08-01), Uehara et al.
patent: 5091431 (1992-02-01), Tulshian et al.
patent: 5442044 (1995-08-01), Hoover et al.
patent: 6001830 (1999-12-01), Lee et al.
patent: 6106864 (2000-08-01), Dolan et al.
patent: 6130223 (2000-10-01), Jonas et al.
patent: 6184338 (2001-02-01), Schwindeman et al.
patent: 6288078 (2001-09-01), Walsh et al.
patent: 6432957 (2002-08-01), Kodoma et al.
patent: 6465486 (2002-10-01), Baxter et al.
patent: 6566360 (2003-05-01), Niewohner et al.
patent: 6777419 (2004-08-01), Jonas et al.
patent: 2001/0047013 (2001-11-01), Lang et al.
patent: 2002/0058668 (2002-05-01), Yuan
patent: 2002/0127593 (2002-09-01), Reich et al.
patent: 2003/0187261 (2003-10-01), Havlicek et al.
patent: 2004/0002990 (2004-01-01), Sander et al.
patent: 2004/0023990 (2004-02-01), Eggenweiler et al.
patent: 2004/0029900 (2004-02-01), Jonas et al.
patent: 2004/0063730 (2004-04-01), Eggenweiler et al.
patent: 2004/0077664 (2004-04-01), Eggenweiler et al.
patent: 0296811 (1987-06-01), None
patent: 0297858 (1987-07-01), None
patent: 0349239 (1988-07-01), None
patent: 319479 (1989-06-01), None
patent: 400661 (1990-05-01), None
patent: 0937459 (1999-08-01), None
patent: 1072595 (2001-01-01), None
patent: 0579496 (2001-11-01), None
patent: 1176142 (2002-01-01), None
patent: 1176147 (2002-01-01), None
patent: 1241170 (2002-09-01), None
patent: 1348707 (2003-10-01), None
patent: 2638745 (1988-11-01), None
patent: 03142277 (1989-10-01), None
patent: 2002255932 (2002-09-01), None
patent: WO 8605518 (1986-09-01), None
patent: WO 8605519 (1986-09-01), None
patent: WO 9301181 (1993-01-01), None
patent: WO 93/06104 (1993-04-01), None
patent: WO 93/07149 (1993-04-01), None
patent: WO 93/12095 (1993-06-01), None
patent: WO 94/00453 (1994-01-01), None
patent: WO 94/05661 (1994-03-01), None
patent: WO 95/19978 (1995-07-01), None
patent: WO 9616657 (1996-06-01), None
patent: WO 9817668 (1998-04-01), None
patent: WO 98/49166 (1998-11-01), None
patent: WO 9928325 (1999-06-01), None
patent: WO 99/45006 (1999-09-01), None
patent: WO 9954333 (1999-10-01), None
patent: WO 00/24745 (2000-05-01), None
patent: WO 01/27112 (2001-04-01), None
patent: WO 01/27113 (2001-04-01), None
patent: WO 0123389 (2001-04-01), None
patent: WO 01/32646 (2001-05-01), None
patent: WO 01/47901 (2001-07-01), None
patent: WO 0147495 (2001-07-01), None
patent: WO 02/10171 (2002-02-01), None
patent: WO 0213798 (2002-02-01), None
patent: WO 02/42292 (2002-05-01), None
patent: WO 02066481 (2002-08-01), None
patent: WO 02102314 (2002-12-01), None
patent: WO 2004006867 (2004-01-01), None
patent: WO 2004096810 (2004-11-01), None
Vippagunta et. al. (Advanced Drug Delivery Reviews, 2001, 48, 3-26).
Thayer, A.M. (Chem. & Eng. News, 2007, 85(25), 31-34).
Organic Reactions, vol. 41 and vol. 42, p. 42, 1992.
Chambers et al. Journal Organic Chemistry,Selective Sequential Demasking of the Ester Functions of 1-Methyl-3,4,5-tris(methoxycarbonyl)pyrazole, 50, 4736-4738, 1985.
Zeitschrift fur Chemie 28; 2; 59-60, 1988.
Webber, R., et.al., Journal Med. Chem.,Substituted 2-Iminopiperidines as Inhibitors of Human Nitric Oxide Synthase Isoforms, 41 (1); 96-101, 1998.
Singh, B., et. al., J Het. Chem.,Three Convenient and Novel Syntheses of 4-Amino-2-arylpyrimidines, 14; 1413; 1977.
Hara, H., et. al., J. Het. Chem.,On the Amination of Azaheterocycles. A New Procedure for the Introduction of an Amino Group(1), 19; 1285; 1982.
Orozco, M., et. al., J. Pharmaceutical Science,Quantum Chemical Study of the Electronic and Conformational Characteristics of Adenosine and 8-Substituted Derivatives: Functional Implications in the Mechanism of Reaction of Adenosine Deaminase, 79(2), 133-137, 1990.
Orozco, M., et. a., Quantitative Struct.-Act. Relat.,Theoretical Approximation to the Reaction Mechanism of Adenosine Deaminase, 8: 109-114, 1989.
Orozco, M., et. al., Molecular Pharmacology,Theoretical Study of the Protonation and Tautomerization of Adenosine, Formycin, and Their 2-NH2and 2-F Derivatives: Functional Implications in the Mechanism of Reaction of Adenosine Deaminase, 35(2): 257-264, 1988.
Upadhya, K., et. al., Nucleic Acids Research,Synthesis of 5-chloroformycin A, 5-chloro-2′-deoxyformycin A and certain related 5,7-disubstituted 3-β-D-ribofuranosylpyrazolo[4,3-d]pyrimidines from formycin A, 14(4): 1747-1764, 1986.
Secrist III, J., et. al., Journal Med. Chem.,2-Fluoroformycin and 2-Aminoformycin. Synthesis and Biological Activity, 28(11): 1740-1742, 1985.
Diederich, F.,Metal-Catalysed Cross-Coupling Reactions, Wiley-VCH, 1998.
Norris, T., et. al., J. Chem. Soc. Perkin Trans. 1,Synthesis of trovafloxacin using various(1α, 5α, 6α)-3-azabicyclo[3.1.0]hexane derivatives, 1615-1622, 2000.
Bochis, R., et. al., J. Med. Chem.,Substituted Imidazo[1,2-α]pyridine-2-carbamate Anthelmintics, 24(12) 1518-1521, 1981.
Yakovlev, M., et. a., Chemistry of. Heterocyclic Compound,Synthesis of Substituted 2,5-Diazabicyclo[2.2.1]Heptanes, 36(4): 429-431, 2000.
Smith, S., et. al., Tetrahedron Letters,Tandem cyclisation and [2,3]-Stevens rearrangement to 2-substituted pyrrolidines, 43, 899-902, 2002.
Barlocco, D., et. al., J. Med. Chem.,Mono- and Disubstituted-3,8-diazabicyclo[3.2.1]octane Derivatives as Analgesics Structurally Related to Epibatidine: Synthesis, Activity, and Modeling, 41, 674-681, 1998.
Baraldi, P., et. al., IL Farmaco,Synthesis, Antibacterial Activity and Structure-Activity Relationships ofN-Substituted 4-Diazo-Pyrazole-5-Carboxamides, 46 (11), 1337-1350, 1991.
Brown, H., et. al., J. Org. Chem.,Hydroboration. 71. Hydroboration of Representative Heterocyclic Olefins with Borane-Methyl Sulfide, 9-Borabicyclo[3.3.1]nonane, Dicyclohexylborane, and Disiamylborane. Synthesis of Heterocyclic Alcohols, 50, 1582-1589, 1985.
H.C.Van Der Plas, Rec.1. Trav. Chim. Pays-Bas.,Syntheses of Amino and Bromo Derivatives of 4-methyl-,4-t-butyl-and 4-phenyl-pyrimidine, 84, 1101-1106, 1965.
Dumaitre, B., et. al., Journal of Medicinal Chemistry, American Chemical Society,Synthesis and Cyclic GMP Phosphodiesterase Inhibitory Activity of a Series of 6-Phenylpyrazolou3, 4-Dpyrimidones, 39(8), 1635-1644, 1996.
Czarniecki, M., et. al., Annu. Rep. Med. Chem.,Inhibitors of Types I and V Phosphodiesterase: Elevation of cGMP as a Therapeutic Strategy, 31, 61-70, 1996.
Bell Andrew Simon
Brown David Graham
Fox David Nathan Abraham
Lu Hwang Fun
Marsh Ian Roger
Benson Gregg C.
Coleman Brenda L
Moore Susanna
Pfizer Inc
Ronau Robert T.
LandOfFree
Pyrazolo[4,3-D]pyrimidines does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Pyrazolo[4,3-D]pyrimidines, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Pyrazolo[4,3-D]pyrimidines will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4139063